Global Air Charter Services Market Procurement Intelligence Report to Have an Incremental Spend of USD 5 Billion

The Air Charter Services market is growing at a CAGR of 3.86% during the five-year forecast period. A targeted strategic approach to Air Charter Services sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic.

Download free sample report
Air Charter Services Market Procurement Research Report
Air Charter Services Market Procurement Research Report

Key Highlights Offered in the Report:

Information on how to identify strategic and tactical negotiation levels that will help achieve the best prices.
Gain information on relevant pricing levels, detailed explanation on pros and cons of prevalent pricing models.
Methods to help engage with the right suppliers and discover KPI’s to evaluate incumbent suppliers.

Get a free sample report for more information

Insights into buyer strategies and tactical negotiation levers:
Several strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for the Air Charter Services market. The report also aids buyers with relevant Air Charter Services pricing levels, pros, and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.

For more insights on buyer strategies and tactical negotiation levers, www.spendedge.com/report/air-charter-services–sourcing-and-procurement-intelligence-report

Key Drivers and Trends Fueling Market Growth:
The pressure from substitutes and a moderate level of threat from new entrants has resulted in the low bargaining power of suppliers.

Price forecasts are beneficial in purchase planning, especially when supplemented by the constant monitoring of price influencing factors.

Identify favorable opportunities in Air Charter Services TCO (total cost of ownership).

Expected changes in price forecast and factors driving the current and future price changes.
Identify pricing models that offer the most rewarding opportunities.

To get instant access to over 1000 market-ready procurement intelligence reports without any additional costs or commitment.

Subscribe Now for Free

Some of the top Air Charter Services suppliers listed in this report:
This Air Charter Services procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.

VistaJet
Air Partner Plc
Delta Private Jets Inc

Get the Details That You Are Looking for:
Buy our detailed market analysis report to uncover:

Changing market landscape with yearly forecast till 2025.
Analyze the market’s competitive and vendor landscape.
How much marketing budget to set aside for geographical market expansion?
Understanding the most adopted procurement strategies by buyers across industries.

Cavinder Twins Partner With Fantasy Sports App Sleeper In First Deal Of Its Kind

Fresno State basketball players Hanna and Haley Cavinder have partnered with Sleeper, the fastest organically growing fantasy sports company in the United States. The collaboration marks the first paid sponsorship between a college athlete and a fantasy sports brand.

CAVINDER TWINS PARTNER WITH FANTASY SPORTS APP SLEEPER IN FIRST DEAL OF ITS KIND

The Cavinders are not only two of the most talented basketball players in the country, they also enjoy two of the largest social media followings among their peers. It’s that combination of on-court talent and off-court influence that drew the attention of Sleeper CEO Nan Wang and his team.

“Hanna and Haley are two of the brightest stars you will find, both on and off the court. We are thrilled to have them as part of the Sleeper family,” said Wang.

Sleeper has been on a meteoric rise since launching their fantasy leagues in 2018. In 2021, the company has more than doubled its user base, exceeding 3 million active users, while at the same time boasting a top-50 user retention ranking in the app store. A major part of that success comes from the company’s innovative take on traditional games like fantasy basketball. In what the company calls “Game Pick,” users choose just one game per week for each starter to count towards their weekly score, reducing the amount of work required per user.

Sleeper’s mission since its inception has been to bring people together through sports, and this partnership is no different. As part of the collaboration, the Cavinder twins will be running a fantasy basketball league of their own, in conjunction with their friends and family, using the Sleeper platform.

“Teaming up with Sleeper made sense for us because it brings Haley and I closer to the things we love most in this world: our friends, family, and basketball. At Sleeper it’s not just about winning or losing your league, it’s about bringing people together and creating memories. What more could we ask for in a partner?”

Fans of the Cavinders will be able to follow the results of their newly formed fantasy league throughout the NBA season, as both Hanna and Haley will be posting updates on their teams’ progress via social media.

ABOUT SLEEPER
Sleeper is a fantasy sports app focused on bringing people together through sports and gaming. With fantasy leagues covering the NFL, NBA, college basketball and League of Legends, Sleeper has become the fastest organically growing fantasy platform in the world, while earning some of the highest levels of engagement per user in the industry. At Sleeper, it’s not just about sports; it’s about building personal connections and lasting memories.

Update on U.S. FDA Review of Biologics License Application

Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that they were unable to complete review of the Biologics License Application (BLA) for bimekizumab for the treatment of moderate to severe plaque psoriasis by the Prescription Drug User Fee Action (PDUFA) date of October 15, 2021.

The Agency has determined that on-site inspections of the European manufacturing facilities for bimekizumab are required before the FDA can approve the application. The FDA indicated that they were unable to conduct the inspections during the current review cycle due to COVID-19 related restrictions on travel. Therefore, the FDA is deferring action on the application until the inspections can be completed. In the letter, the Agency cited only travel restrictions and its inability to complete facility inspections as the reason for the deferral. The BLA for bimekizumab remains under review.

Under FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, the Agency may defer action on a pending application when a facility inspection is planned but cannot be completed by the PDUFA goal date due to COVID-related travel restrictions, provided that no deficiencies have been identified and the application otherwise satisfies the requirements for approval.1

“We are currently in contact with the FDA to schedule the inspections of our manufacturing facilities as soon as possible,” said Prof. Dr. Iris Loew Friedrich, Chief Medical Officer and Executive Vice President, Development UCB. “We have provided the Agency with the manufacturing schedules through the first quarter of 2022, and we are eager to assist the FDA to allow its assessment of bimekizumab to be finalized. We are committed to bringing bimekizumab to patients in the U.S. with moderate to severe plaque psoriasis as soon as possible.”

In August 2021, bimekizumab received marketing authorization in countries of the European Union (EU)/European Economic Area (EEA) and Great Britain, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2,3 Bimekizumab is not approved by any other regulatory authority outside the EU/EEA and Great Britain. Regulatory reviews are underway in Australia, Canada, Switzerland and Japan.

UCB’s financial guidance for 2021 and 2025 remains unchanged.

About Psoriasis
Psoriasis is a common, chronic inflammatory disease with primary involvement of the skin.4 This skin condition affects men and women of all ages and ethnicities.4 Psoriasis signs and symptoms can vary but may include red patches of skin covered with silvery scales; dry, cracked skin that may bleed; and thickened, pitted or ridged nails.5 Psoriasis also has a considerable psychological and quality-of-life impact, potentially affecting work, recreation, relationships, sexual functioning, family and social life.6

Unmet needs remain in the treatment of psoriasis. A population-based survey identified that approximately one in three psoriasis patients reported that their primary goals of therapy, including keeping symptoms under control, reducing itching and decreasing flaking, were not met with their current treatment.7

About bimekizumab
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively and directly inhibits both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.8 Selective inhibition of IL-17F in addition to IL-17A has been shown to suppress inflammation to a greater extent than IL-17A inhibition alone.8,9

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,400 people in nearly 40 countries, the company generated revenue of €5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA.

Forward looking statements UCB
This press release may contain forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Tao of Chinese Calligraphy is the Way to the Whole World

The exhibition “From Inception: Wang Dongling 60 Years of Calligraphy” opens at the Zhejiang Art Museum on October 16, 2021. This exhibition focuses on China Academy of Art’s professor, Wang Dongling’s 60-year exploration of calligraphy art, from traditional calligraphy to other styles such as Chaos-Writing (Entangled Calligraphy), Big Writing, Silver Gelatin Calligraphy, Calligraphy on Bamboo Stalks, Calligraphy using immersive virtual reality, and so on. The long span of time covered by the exhibits, the diversity of styles, the depth of academic research, and the novelty of media experimentation are unprecedented not only in Wang Dongling’s solo exhibition history, but also in Chinese calligraphy exhibition history.

For a calligraphy artist with six decades’ experience, Wang Dongling always remains open-minded to emerging media technologies. In his view, a conversation with new technologies is a conversation with the future. In October 2015, Tim Cook, CEO of Apple Inc., came to Hangzhou and paid a visit to Wang Dongling to learn Chinese calligraphy from him. The event led to a heated discussion by people from all walks of life, domestically and internationally. Earlier in 2013, Wang Dongling cooperated with the renowned new media artist Jeffrey Shaw on “Big Writing.” In 2020, during the global rage of Covid-19, he was invited by American director Peter Sellars to participate in the trans-disciplinary art project titled “This body is so impermanent…”

Wang Dongling has been conducting extensive and in-depth calligraphy experiments since the 1990s. He never regards calligraphy as a kind of legacy, but promotes the open, experimental potential of calligraphy so that calligraphy, as an ancient art form, can become a member of the contemporary art world.

In Exhibition Hall No. 4 of Zhejiang Art Museum , named “Fantasy Land of Calligraphy,” is a world of colored glaze illuminated by both lights and colors: from abstract ink paintings to silver gelatin calligraphy, to the use of materials like stainless steel mirror and clear acrylic, and to the numerous representations through new media such as iPad calligraphy and motion capture digital art.

In Exhibition Hall No. 5, named “Scholar’s Snow Cave,” the small-sized works in Regular Script and big-sized works in Cursive Script encompass calligraphy genres such as album leaves, scrolls, tablet inscriptions, screens, etc. Created with deliberate, meticulous laws and discipline as well as a grandiose, peculiar beauty, these works express the artist’s profound immersion and training in the calligraphy tradition and gesture toward bold possibilities for innovation.

The hanging scrolls in four scripts in Exhibition Hall No.6 showcase the six decades’ creative journey of Wang Dongling. The newly created “Big Writing” installation in commemoration of the 2,500th anniversary of Confucius’ passing represents the contours of the journey of Confucius. The shift from Cursive Script of profound traditional depth to Entangled Calligraphy is also a response to the artist’s personal life journey.

Wang Dongling discussed teaching foreign students and the enlightenment that resulted from it: “In 1981, I taught calligraphy to foreign students. Foreign students inspired me to look at calligraphy in new ways and to consider how people outside of our circle view art. My usual calligraphy practice had become too constrained and monotonous for me. I believe that new ideas should be developed to strengthen and broaden the artistic expression of calligraphy. After a conversation with a bearded Colombian student in 1983, I began “secretly” practicing modern calligraphy. “Powerful and Unconstrained (Tian Ma Xing Kong)” was my first modern calligraphy piece. I had a starting point to broaden my calligraphy skills from then on.”

In the 1990s, he personally taught at the University of Minnesota and numerous other higher institutions and actively participated in overseas academic activities on contemporary art. He said, “I’ve taught calligraphy at several universities in the United States, Germany, and Japan. I’ve taught foreign students pen and ink skills in Chinese calligraphy, but I don’t want them to become “Chinese calligraphers” who can imitate classical works of famous writers such as Yan Zhenqing well. Instead, I want them to be able to wield this most basic and traditional artistic language of China once they’ve mastered and internalized it, so that their creativity can flourish and enrich their own artistic creation”. When discussing his experience teaching calligraphy in the United States, he stressed that “some Westerners write calligraphy not to write Chinese characters, but to draw abstract images, and they learn calligraphy not to be a Chinese calligrapher, but to learn art techniques and inspiration from calligraphy to create other art. I began to realize that calligraphy is not only a dialogue with tradition, but also with the global civilization. It is not only about a dialogue with contemporary art but also with digital technology. ”

Since the new century, he personally initiated the project titled “Big Characters Travel the World,” a plan to construct writing scenes of Chinese calligraphy at the most important art institutions around the globe, promoting academic communication between calligraphy and international art circle. In his view, Chinese calligraphers must proactively and confidently enter onto the scenes of international art for mutual illumination and inspiration in cross-cultural exchange. It is only by “manifesting the common through differences” that calligraphy can return to its true origin in cultural dialogues and make due contributions to the culture of humanity as a whole. As a result, calligraphy must transcend “the controversy between east and west.”

His works are represented in the collections of the National Art Museum of China, the Palace Museum (Taipei), Peking University, the British Museum, the Victoria and Albert Museum, the Metropolitan Museum of Art, the Library and Archives Canada, The Art Institute of Chicago, the Vancouver Art Gallery, as well as in universities such as Harvard, Yale, Stanford, and Berkeley.

President of the China Academy of Art, Gao Shiming said, “How do we revitalize the unique intellectual genealogy of Chinese calligraphy in the spirit of cosmopolitan sharing? How can we make calligraphy an always sustainable and open cause? With his indefatigable efforts and constant experiments during the last six decades, Wang Dongling provides us with a meaningful example. For sixty years, he has been tirelessly exploring within the great tradition of Chinese calligraphy and constantly searching for inspirations across the grand horizon of world art. Through the dialectics of “Writing•Non-writing” he returns to the vital fountainhead of calligraphy and opens up its creative space. For calligraphy, he has a grand vision: to revitalize the great tradition of calligraphy for contemporary audiences, to spread the Tao of calligraphy in Chinese civilization to the whole world. For himself, he has a firm position: to remain indifferent to praises and condemnations, favors and shames, to live as he wishes, to do justice to this life.”

InnovAge Holding Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action

Robbins Geller Rudman & Dowd LLP announces that purchasers of InnovAge Holding Corp. (NASDAQ: INNV) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with InnovAge’s March 2021 initial public offering (“IPO”) have until December 13, 2021 to seek appointment as lead plaintiff in the InnovAge class action lawsuit. The InnovAge class action lawsuit – captioned McLeod v. InnovAge Holding Corp., No. 21-cv-02770 – charges InnovAge, certain of its officers, and the underwriters of InnovAge’s IPO with violations of the Securities Act of 1933. The InnovAge class action lawsuit was commenced on October 14, 2021 in the District of Colorado.

If you wish to serve as lead plaintiff of the InnovAge class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] Lead plaintiff motions for the InnovAge class action lawsuit must be filed with the court no later than December 13, 2021.

CASE ALLEGATIONS: InnovAge operates a healthcare delivery platform that purportedly takes a patient-centered care approach to improve the quality of care that participants receive. In its IPO, InnovAge sold approximately 18,995,901 shares of common stock at a price of $21.00 per share. The proceeds from the IPO were purportedly to be used to repay certain debt and for general corporate purposes, including working capital, operating expenses, and capital expenditures.

The InnovAge class action lawsuit alleges that InnovAge’s Registration Statement was materially false and misleading and omitted that: (i) certain of InnovAge’s facilities failed to provide covered services, provide accessible and adequate services, manage participants’ medical situations, and oversee use of specialists; (ii) as a result, InnovAge was reasonably likely to be subject to regulatory scrutiny, including by the Centers for Medicare and Medicaid Services (“CMS”); (iii) thus, there was a significant risk that CMS would suspend new enrollments pending an audit of InnovAge’s services; and (iv) given the foregoing, defendants’ positive statements about InnovAge’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On September 21, 2021, InnovAge revealed that the CMS had “determined to suspend new enrollments at [the Company’s] Sacramento center based on deficiencies detected in [a recent] audit.” The Company stated that these deficiencies “related to participant quality of care.” On this news, InnovAge’s stock price fell approximately 25%, damaging investors.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased InnovAge common stock pursuant and/or traceable to the Registration Statement issued in connection with the IPO to seek appointment as lead plaintiff in the InnovAge class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the InnovAge class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the InnovAge class action lawsuit. An investor’s ability to share in any potential future recovery of the InnovAge class action lawsuit is not dependent upon serving as lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other securities plaintiffs’ firm. Please visit https://www.rgrdlaw.com/firm.html for more information.

Did You Suffer a Loss in Excess of $100,000? Contact Johnson Fistel About Leading Katapult Class Action Lawsuit

Shareholder rights law firm Johnson Fistel, LLP announces that purchasers of Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ: KPLT) between December 18, 2020, and August 10, 2021, have until October 26, 2021, to file a lead plaintiff motion.

[click here to join this action]

The filed complaint alleges that Katapult Holdings, Inc. made materially false and misleading statements and failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult’s assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers’ future buying behavior; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and lacked a reasonable basis.

A lead plaintiff will act on behalf of all other class members in directing the Katapult class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor’s ability to share any potential future recovery of the Katapult class action lawsuit is not dependent upon serving as lead plaintiff.

If you suffered a substantial loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471

“You can get vaccinated when you feel more comfortable, but otherwise, there’s no specific complications to getting the vaccination,” he added.

Will Covid-19 mRNA vaccines harm the foetus? Are booster shots recommended for pregnant women? These were some questions raised by pregnant women and members of the public during a webinar on Saturday (Oct 16) organised by the College of Clinician Scientists under the Academy of Medicine Singapore.

Here are some questions answered by doctors.

A: Unvaccinated pregnant women – especially those at the later stages of their pregnancy and who have pre-existing medical conditions – are at higher risk of needing intensive care or mechanical ventilation, should they contract Covid-19. During the later stages of pregnancy, the growing foetus may press the uterus against the diaphragm – a respiratory muscle – causing it to be pushed up slightly, said senior consultant Citra Mattar from the National University Hospital obstetrics and gynaecology (O&G) department’s division of maternal foetal medicine.

Covid-19 also significantly increases the risk of pregnant women developing blood clots. A clot in the lungs could be life-threatening, said Professor Tan Hak Koon, KK Women’s and Children’s Hospital’s (KKH) O&G division. “Pregnant women infected with Covid-19 are also twice as likely to deliver preterm because the doctors have to deliver their babies earlier to help their lungs and heart function better,” he added.
Q: If mummy gets Covid-19, will the baby get it too?

A: Data from last year and early this year shows that the risk of transmission from pregnant mother to the foetus is about 1 per cent to 4 per cent, said Associate Professor Zubair Amin, head and senior consultant at the neonatology department in the Khoo Teck Puat – National University Children’s Medical Institute at the National University Hospital.

“But (recent) anecdotal data is showing that this percentage is probably too low an estimate. It seems that with the (more infectious) Delta variant and the current wave of infections, the risk of transmission is much higher,” he added.

Transmission can happen during pregnancy, at the time of delivery, or post delivery during breastfeeding or direct contact.

Babies are at increased risk of admission to the neonatal intensive care unit, so the mothers have to grapple with being separated from their newborns.
Q: How would Covid-19 in pregnant women affect newborns?

A: Children are known to have a lower risk of mortality and severe illness from Covid-19, compared with older people. But infected newborns are at higher risk compared with older children, said Prof Amin.

Existing data shows that babies’ risk of mild symptoms such as runny nose and cough is 40 per cent to 50 per cent, while the chance of moderate to severe symptoms such as breathing difficulties and poor feeding is at 12 per cent to 40 per cent.

Moderate and severe complications in an infected newborn would include pneumonia, respiratory distress, vomiting, diarrhoea, occasionally low blood counts and collapsed lungs, said Associate Professor Thoon Koh Cheng, head of the infectious disease service in the department of paediatrics at KK Women’s and Children’s Hospital. Prof Thoon did not take part in the webinar.
More on this topic
More unvaccinated pregnant women with Covid-19 in hospital
Woman who gave birth in isolation ward urges others to get Covid-19 vaccine
Q: How do mRNA vaccine side effects differ for pregnant women?

A: Side effects, such as sore arm, fever and headaches, are similar to the rest of the population.

But if some women – during the course of pregnancy – are already experiencing severe nausea or are feeling very unwell or very lethargic, they should wait a week or two until those symptoms subside, before getting the vaccine. This is because the vaccine could exacerbate their nausea and morning sickness, for instance, said Associate Professor Mahesh Choolani, president of the College of Clinician Scientists.Q: Are pregnant women advised to get booster shots?

A: International guidelines are currently recommending that all pregnant women have the booster if fully vaccinated, said Associate Professor Tan Lay Kok, head of the maternal foetal medicine department at KKH.

Currently, eligible people aged 30 and above will be invited to take Covid-19 vaccine booster shots, as long as they have had their second jab at least six months ago.

Some studies have shown that antibodies from vaccinated mothers can be transferred to babies via the placenta or through breast milk.

Prof Tan Lay Kok added: “So there is little reason to suspect anything untoward happening from a booster, and the purpose of the booster is to boost or maintain antibody levels. So if you are eligible for the booster, go for it.”

 

 

https://online-tvchannel.org/

Russian daily Covid-19 deaths hit record high but lawmakers rule out lockdown

Russia has reported a record number of Covid-19 cases and deaths in the past 24 hours, data from the country’s Coronavirus Response Center showed Saturday.
In the past 24 hours, 1,002 people have died with Covid-19. The previous record was reported Friday, with 999 Covid-related deaths in a 24-hour period.
The country has also reported a new all-time record of daily coronavirus cases for the third day in a row. On Saturday, authorities reported that 33,208 new cases of Covid-19 had been diagnosed in the past day.

Despite the record numbers, lawmakers continue to reject the introduction of a country-wide lockdown. The speaker of Russia’s Federation Council, Valentina Matvienko, said the move was unreasonable.

Putin says Russia needs to speed up vaccination for Covid-19
Putin says Russia needs to speed up vaccination for Covid-19
“The situation is not easy. But there are no grounds for introducing a federal lockdown,” Matvienko reportedly said, according to state news agency TASS.
Russian President Vladimir Putin on Tuesday urged lawmakers to convince the country’s citizens to get vaccinated.
“You know that the number of infections is growing in many regions and medical specialists are working in difficult conditions. We all know well that vaccination can save us from the virus and from a severe course of the disease. It is necessary to step up the vaccination pace,” Putin said.
Russia has lagged behind much of the world when it comes to getting its population inoculated, despite being the first country in the world to approve a coronavirus vaccine, Sputnik V, for use in August 2020.
Not getting vaccinated against Covid-19 is “really irresponsible,” Kremlin spokesperson Dmitry Peskov said Thursday. But as long as doctors cope with the flow of patients with Covid-19, emergency measures will not be taken, he added.
Peskov also said Thursday that Putin would get a booster shot when doctors deem it necessary, according to TASS.
“Everything will depend on the recommendations of specialists. The President is very attentive to this. As soon as specialists come to an understanding of the need for revaccination, this will be done,” Peskov said, in answer to a question.
Russia’s official death toll due to Covid-19 now stands at 222,315 since the beginning of the pandemic, the highest number in Europe. The actual number is believed to be much higher though, due in part to the way Russia classifies coronavirus deaths.
The total number of identified Covid-19 cases in Russia has risen to 7,958,384 since the beginning of the pandemic.
Data from Russia’s coronavirus taskforce released Saturday suggests around 45% of the population may have immunity to Covid-19 through vaccination or infection.

Some regions in Russia are introducing certain restrictions locally due to an increase of Covid-19 infections. Several regions have introduced QR codes allowing only vaccinated people and recovered patients to visit restaurants and public events.
Events with more than 3,000 participants are banned throughout the country in connection with the pandemic, the head of the Rospotrebnadzor health watchdog, Anna Popova, said on October 4, according to state media outlet RIA Novosti. For some regions, the restrictions are tougher depending on the severity of the coronavirus situation

 

 

https://online-tvchannel.org/

askST: If mum gets Covid-19, will the unborn baby get it too?

Will Covid-19 mRNA vaccines harm the foetus? Are booster shots recommended for pregnant women? These were some questions raised by pregnant women and members of the public during a webinar on Saturday (Oct 16) organised by the College of Clinician Scientists under the Academy of Medicine Singapore.

Here are some questions answered by doctors.
Q: Why are unvaccinated pregnant women at higher risk of Covid-19 complications?

A: Unvaccinated pregnant women – especially those at the later stages of their pregnancy and who have pre-existing medical conditions – are at higher risk of needing intensive care or mechanical ventilation, should they contract Covid-19. During the later stages of pregnancy, the growing foetus may press the uterus against the diaphragm – a respiratory muscle – causing it to be pushed up slightly, said senior consultant Citra Mattar from the National University Hospital obstetrics and gynaecology (O&G) department’s division of maternal foetal medicine.

Covid-19 also significantly increases the risk of pregnant women developing blood clots. A clot in the lungs could be life-threatening, said Professor Tan Hak Koon, KK Women’s and Children’s Hospital’s (KKH) O&G division. “Pregnant women infected with Covid-19 are also twice as likely to deliver preterm because the doctors have to deliver their babies earlier to help their lungs and heart function better,” he added.
Q: If mummy gets Covid-19, will the baby get it too?

A: Data from last year and early this year shows that the risk of transmission from pregnant mother to the foetus is about 1 per cent to 4 per cent, said Associate Professor Zubair Amin, head and senior consultant at the neonatology department in the Khoo Teck Puat – National University Children’s Medical Institute at the National University Hospital.

“But (recent) anecdotal data is showing that this percentage is probably too low an estimate. It seems that with the (more infectious) Delta variant and the current wave of infections, the risk of transmission is much higher,” he added.

Transmission can happen during pregnancy, at the time of delivery, or post delivery during breastfeeding or direct contact.

Babies are at increased risk of admission to the neonatal intensive care unit, so the mothers have to grapple with being separated from their newborns.
Q: How would Covid-19 in pregnant women affect newborns?

A: Children are known to have a lower risk of mortality and severe illness from Covid-19, compared with older people. But infected newborns are at higher risk compared with older children, said Prof Amin.

Existing data shows that babies’ risk of mild symptoms such as runny nose and cough is 40 per cent to 50 per cent, while the chance of moderate to severe symptoms such as breathing difficulties and poor feeding is at 12 per cent to 40 per cent.

Moderate and severe complications in an infected newborn would include pneumonia, respiratory distress, vomiting, diarrhoea, occasionally low blood counts and collapsed lungs, said Associate Professor Thoon Koh Cheng, head of the infectious disease service in the department of paediatrics at KK Women’s and Children’s Hospital. Prof Thoon did not take part in the webinar.
More on this topic
More unvaccinated pregnant women with Covid-19 in hospital
Woman who gave birth in isolation ward urges others to get Covid-19 vaccine
Q: How do mRNA vaccine side effects differ for pregnant women?

A: Side effects, such as sore arm, fever and headaches, are similar to the rest of the population.

But if some women – during the course of pregnancy – are already experiencing severe nausea or are feeling very unwell or very lethargic, they should wait a week or two until those symptoms subside, before getting the vaccine. This is because the vaccine could exacerbate their nausea and morning sickness, for instance, said Associate Professor Mahesh Choolani, president of the College of Clinician Scientists.

“You can get vaccinated when you feel more comfortable, but otherwise, there’s no specific complications to getting the vaccination,” he added.
Q: Are pregnant women advised to get booster shots?

A: International guidelines are currently recommending that all pregnant women have the booster if fully vaccinated, said Associate Professor Tan Lay Kok, head of the maternal foetal medicine department at KKH.

Currently, eligible people aged 30 and above will be invited to take Covid-19 vaccine booster shots, as long as they have had their second jab at least six months ago.

Some studies have shown that antibodies from vaccinated mothers can be transferred to babies via the placenta or through breast milk.

Prof Tan Lay Kok added: “So there is little reason to suspect anything untoward happening from a booster, and the purpose of the booster is to boost or maintain antibody levels. So if you are eligible for the booster, go for it.”

 

 

https://online-tvchannel.org/

He added that this can be done without erasing their patent rights or royalties.

Should the makers of COVID-19 vaccine be compelled to share their methods with the world?

Leading vaccine doctors won’t say.

President Joe Biden supports waiving patent protections for the vaccines, which have brought down hospitalizations and death but remain in the hands of a few companies lacking capacity to produce them on a global scale.

Though wealthy nations have high rates of vaccination, dozens of poor countries remain below 5% vaccination rates, rapidly dividing the planet into a world of COVID-19 haves and have-nots, and notably by color.

Beyond inequity, critics say this creates a false sense of security for Americans now receiving third doses.

The longer poor nations of color go without, they argue, the greater the likelihood that a vaccine-resistant variant will make its way into the U.S. health care system, undoing all progress.

As Mayo Clinic’s Dr. Greg Poland said recently, “this is a we, not me situation,” one in which the fate of distant others affects that of patients here within the U.S.

It’s why earlier this week, a group of U.S. senators, led by Sen. Elizabeth Warren, signed a letter urging Biden to release patent protections on the Moderna vaccine, which received billions of dollars in federal aid to get to market.

They were joined in calling for sharing of intellectual property by Dr. Tom Frieden, former director of the Centers for Disease Control and Prevention.

In a Washington Post piece published Tuesday, Oct. 12, Frieden said the fact that just 4% of the world’s 6.5 billion doses of COVID-19 vaccine have gone to poor countries was “morally indefensible,” and that it could cause millions of added deaths.

“The only responsible way forward,” Frieden wrote of drug giants Pfizer and Moderna, “is for them to transfer their vaccine technology to other companies that can rapidly increase production.”

He added that this can be done without erasing their patent rights or royalties.
Doctors who speak up, and others who remain silent

What do influential vaccinologists believe about sharing vaccine technology?

Poland, Mayo’s face of vaccine messaging and a global authority in the research and development of the medicines, won’t say. He declined comment through a spokesperson.

Mayo’s Robert Nellis cited a separation within Mayo between opining on medical practice and public policy, saying that “Mayo generally does not comment on government policy or positions.”

Nor would Dr. Paul Offit lend his support to sharing IP. A pediatrician at Children’s Hospital in Philadelphia and past member of the CDC’s advisory committee on vaccines, the prominent American vaccine authority suggested the question of technology transfer was better directed to a medical ethicist.

Other doctors argue that ethics and policy are uniquely a part of stopping the spread of COVID-19.

Dr. Nathan Chomilo, Senior Equity Advisor to the Commissioner, Minnesota Depatment of Health. Photo: MDH
Dr. Nathan Chomilo, Senior Equity Advisor to the Commissioner, Minnesota Depatment of Health. Photo: MDH

“I am an advocate of physicians bringing their professional expertise to bear on these important decisions and policy decisions,” said Dr. Nathan Chomilo, a pediatrician with HealthPartners, and the Senior Equity Advisor to the Commissioner of the Minnesota Department of Health.

“Particularly those who have expertise in vaccine development, distribution, and who hold prominent places in this conversation,” he added. “It really is important for them to be taking this up … to bring professional expertise to bear on this civic discussion.”

Chomilo supports the release of vaccine technology by citing an Aug. 10 letter to the White House signed by 175 medical experts, scientists and civil society leaders, including deans of five leading public health, nursing, and medical schools.

No Mayo clinicians are listed as signers to that letter.

“The United States should explore all legal options,” it read, “to compel mRNA manufacturing originators to share technology and voluntarily license their technology to contract manufacturers around the world, including mRNA manufacturing hubs.”

“There’s a global pandemic,” Chomilo says. “There’s a conversation to be had about how do the structures that were set in place during nonpandemic times need to change … in order to address this threat. Then if they wish folks can go back to what was working before it.”

“They talk about a wartime effort. In a wartime effort, you do what’s necessary. You don’t just stop and say we’ve done our part … It’s not going to be easy in the way our society is structured to get folks to agree to technology transfer, but I think it’s definitely necessary.”
Christian ethics and pandemic medicine

In recent remarks to the media, Mayo’s Poland suggested that getting vaccinated, social distancing and wearing masks constitutes a show of Christian ethics.

He cited a popular passage written by reformation figure Martin Luther when the Black Death returned in 1527 to Wittenburg, Germany.

LEARN MORE: What did Martin Luther say about Christian ethics during a pandemic?

“‘I shall avoid places and persons where my presence is not needed,'” the vaccinologist quoted from the famous letter. “That’s social distancing. Interesting morality there.”

“‘If everyone would help ward off contagion as best he can,'” he continued from the 500-year-old passage, “‘then the death toll would indeed be moderate. But if some are so foolish as to not take precautions — now we would say (that means) masking, distancing and vaccines– and aggravate the contagion, then many will die.'”

Today, the head of the church started by Martin Luther supports the sharing of vaccine technology.

“We cannot abdicate our responsibilities to our sisters and brothers by imagining that the market can be left to resolve the crisis,” read a letter signed last spring by 150 faith leaders, including Lutheran World Federation General Secretary Rev. Dr. Martin Junge.

“We have a moral obligation to reach everyone, in every country.”

The letter was written in support of The Access to COVID-19 Tools (ACT) Accelerator, a World Health Organization proposal that “recognizes and aims to address the requirement for information sharing — whether about technology, intellectual property or manufacturing,” to combat the pandemic.

 

 

https://online-tvchannel.org/